AGTR1 · Western blot design guide

AGTR1 Western Blot Planning Guide

Plan an AGTR1 Western blot around the catalog-observed 41.1 kDa band, image-backed PB9470 evidence, HPA controls, and verified protocol records.

Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
Western blot protocol sheet for AGTR1 (AGTR1): expected band 41.1 kDa, antibody PB9470, and guide-derived SDS-PAGE protocol steps
AGTR1 Western blot protocol sheet — expected band 41.1 kDa, antibody PB9470, controls and PMC citations. Open the full AGTR1 WB guide →

AGTR1 Western Blot Experimental Design Guide

Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running
Expected band 41.1 kDa
Observed band Not reported — verify product WB image
Gel 12-15%
Positive control ⓘ Adipose tissue
Negative control ⓘ Appendix
Important caveats
Reasons your observed band may differ from the expected size.
ⓘ Calculated mass 41.1 kDa
ⓘ Localization Cell membrane
ⓘ Processing / PTM Record-dependent
ⓘ Reactivity Human / Mouse / Rat
Section 1

Real Curated AGTR1 Western Blot Protocols

Start with the molecular-weight rule, then compare verified publication-derived conditions.

Recommended Western blot protocol parameters
Sample / lysateAdipose tissue
Gel %12-15%
Load20-30 µg total protein per lane
TransferSemi-dry, standard transfer
Membrane0.45 µm PVDF
Blocking5% non-fat milk or 5% BSA in TBST
PrimaryPB9470 at datasheet starting dilution
Primary incubationOvernight at 4 °C with gentle agitation
SecondarySpecies-matched HRP conjugate at validated dilution
Wash3 × 5 min in TBST
DetectionChemiluminescent substrate
ExposureBracket exposures to avoid saturation
Section 2

What Is the Expected AGTR1 Western Blot Band Size?

Use the product-observed 41.1 kDa band as the primary planning value and retain the UniProt calculated mass as context.

What am I looking at on my blot?
41.1 kDaMatches the authoritative product WB observation.
41.1 kDa calculatedUse as UniProt context, not as a replacement observed band.
Unexpected additional signalDo not assign identity without orthogonal positive/negative controls.
💡Expected AGTR1 appearancePlan around 41.1 kDa and keep the calculated mass as supporting context.
How each factor affects band size
Catalog-observed band41.1 kDa; use this as the primary experimental expectation.
Calculated mass41.1 kDa from UniProt P30556; retain as context.
Gel selection12-15%; shared with the recommended protocol and poster.
Specificity checkCompare the lead HPA positive and negative controls with PB9470.
Why is my band missing or off?
SituationLikely causeNext action
41.1 kDaMatches the authoritative product WB observation.Confirm with orthogonal controls and the linked product record.
Additional bandMay reflect processing, modification, or non-specific signal.Run a dilution series and compare positive/negative controls.
Weak signalTarget abundance or transfer may be limiting.Verify transfer, increase positive-control abundance, and bracket exposure.

Sample controls for AGTR1 Western blot

🧪Use Adipose tissue as the first positive-control candidate and Appendix as the HPA Not detected negative candidate.
Positive control: Adipose tissue (High)
Negative control: Appendix (Not detected)
HPA protein score determines control status; other expression data is supporting context only.

HPA tissue expression evidence for AGTR1

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

TissueCell typeLevelEvidenceSource
Adipose tissue Reported tissue cells High Protein (HPA) HPA →

Undetected expression · recommended negative controls

TissueCell typeLevelEvidenceSource
Appendix Reported tissue cells Not detected Protein (HPA) HPA →
Bone marrow Reported tissue cells Not detected Protein (HPA) HPA →
Section 3

Advanced AGTR1 Western Blot Tips

Deeper troubleshooting and optimisation questions for AGTR1, answered from its protein features.

Which band should guide the blot?
Use 41.1 kDa, the observation attached to the authoritative PB9470 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 41.1 kDa expectation.
Which positive control should I start with?
Start with Adipose tissue, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Appendix as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for AGTR1 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PB9470 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents

AGTR1 Western Blot Reagents

Human/Mouse/Rat-reactive AGTR1 Western blot reagents with authoritative product imagery.

Real WB data Western blot validation image for AGTR1 using PB9470; observed band 41.1 kDa
Anti-Angiotensin II Type 1 Receptor/AGTR1 Antibody Picoband®
Cat # PB9470

Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.

Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.

References

  1. UniProt P30556
  2. Human Protein Atlas — AGTR1
  3. PB9470 product record
  4. PMC5709427 — Estrogen attenuates AGTR1 expression to reduce pancreatic β-cell death from high glucose (Scientific reports, 2017)
  5. PMC7481885 — Targeting AGTR1/NF-κB/CXCR4 axis by miR-155 attenuates oncogenesis in glioblastoma (Neoplasia (New York, N.Y.), 2020)
  6. PMC5223322 — The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene (BMC cancer, 2017)